S&P Futures
3,922.50 +6.25 (+0.16%) Dow Futures
31,515.00 +28.00 (+0.09%) Nasdaq Futures
12,160.50 +20.00 (+0.16%) Russell 2000 Futures
1,764.70 +3.00 (+0.17%) Crude Oil
107.82 +0.20 (+0.19%) Gold
1,833.40 +3.10 (+0.17%)
Galmed Pharmaceuticals Ltd. (GLMD)
Chart Events
Performance Outlook
| Previous Close | 0.4901 |
| Open | 0.5000 |
| Bid | 0.4500 x 4000 |
| Ask | 0.4921 x 3000 |
| Day's Range | 0.4700 - 0.5000 |
| 52 Week Range | 0.4170 - 3.4200 |
| Volume | |
| Avg. Volume | 96,462 |
| Market Cap | 12.103M |
| Beta (5Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4880 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- PR Newswire
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00
- Zacks
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.
- PR Newswire
Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
TEL AVIV, Israel, May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases reports financial results for the three months ended March 31, 2022.
